Quarterly report · Q1
4543.TEDINET S100RML8
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥215.3bn | 2023-04-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥197.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥29.6bn | 2023-04-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥30.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥29.8bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥29.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.67T | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.58T | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥468.1bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.20T | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.12T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.20T | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.12T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥160.1bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥209.6bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥11.4bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥23.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥19.3bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥16.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥27.5bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥14.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥30.28 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥29.61 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥30.27 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥29.6 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.0% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥1.1bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥40.9bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.9bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥130.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥26.9bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥43.7bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥215.2bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥35.6bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥198m |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥34.5bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥116.8bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥28.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥46.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥197.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 561
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -119000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -16122000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -19314000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | Prior1YTDDuration | 648000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -297000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -315000000 | JPY |
| Redemption of bonds fin cf IFRS | Prior1YTDDuration | － | JPY |
| Redemption of bonds fin cf IFRS | CurrentYTDDuration | -10000000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -1787000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -1786000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -0 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -0 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -13408000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -15422000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -14845000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -27524000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 11920000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 8137000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | 4314000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -27269000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 187322000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 209566000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 160052000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 116825000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 45992000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 34459000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 197278000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | 62000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 197340000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 28011000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 4466000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 3613000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 36092000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -198000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration | 35893000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -2174000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -2449000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReportableSegmentsMember | -4623000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReconcilingItemsMember | 51000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration | -4572000000 | JPY |
| Non recurring profit or loss IFRS | Prior1YTDDuration | -893000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 30427000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 515000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 1264000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | -10000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 29667000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 130584000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |